Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial cancer

Chemotherapy options in advanced urothelial carcinoma (UC) remain limited. Here we evaluated the peptide-based alkylating agent melphalan-flufenamide (mel-flufen) for UC.

Source: Molecular Oncology - January 2, 2016 Category: Cancer & Oncology Authors: Kristina Viktorsson, Carl-Henrik Shah, Therese Juntti, Petra Hååg, Katarzyna Zielinska-Chomej, Adam Sierakowiak, Karin Holmsten, Jessica Tu, Jack Spira, Lena Kanter, Rolf Lewensohn, Anders Ullén Source Type: research